Septicemia and mortality after noncardiac surgery associated with CHA2DS2-VASc score: a retrospective cohort study based on a real-world database

Table 3 Stratified analysis for risk of postoperative adverse events associated with CHA2DS2-VASc score in patients with atrial fibrillation

	Scores	N	Postoperative adverse events*
	Scores	N	Events	Incidence,%	OR (95% CI)^†
Musculoskeletal surgery	0	402	16	4.0	1.00 (reference)
	1	1662	201	12.1	2.43 (1.41–4.19)
	2	3550	500	14.1	2.57 (1.49–4.43)
	3	4527	742	16.4	3.07 (1.78–5.32)
	4	3286	613	18.7	3.42 (1.96–5.94)
	≥ 5	2094	464	22.2	4.04 (2.30–7.09)
Digestive surgery	0	607	47	7.7	1.00 (reference)
	1	2259	342	15.1	1.39 (0.99–1.95)
	2	3633	729	20.1	1.58 (1.12–2.22)
	3	3366	754	22.4	1.51 (1.07–2.14)
	4	1887	492	26.1	1.54 (1.07–2.21)
	≥ 5	1028	315	30.6	1.67 (1.14–2.45)
Neurosurgery	0	221	41	18.6	1.00 (reference)
	1	843	165	19.6	0.87 (0.59–1.29)
	2	1630	389	23.9	0.98 (0.66–1.46)
	3	1773	429	24.2	0.94 (0.63–1.42)
	4	1189	301	25.3	0.92 (0.60–1.42)
	≥ 5	633	184	29.1	1.05 (0.66–1.67)
Respiratory surgery	0	144	15	10.4	1.00 (reference)
	1	399	104	26.1	1.54 (0.82–2.88)
	2	546	182	33.3	1.52 (0.80–2.87)
	3	480	191	39.8	1.65 (0.85–3.19)
	4	348	157	45.1	1.94 (0.98–3.85)
	≥ 5	215	104	48.4	1.82 (0.86–3.81)

CI confidence interval, OR odds ratio
*Postoperative adverse events included with pneumonia, septicemia, urinary tract infection, and 30-day in-hospital mortality
^†Adjusted for all covariates listed in Table 1

ISSN: 1471-2482